Abstract

Approximately 7350 new cases of Hodgkin lymphoma (HL) are diagnosed annually in the United States. The incidence of HL has a bimodal pattern, with the highest incidence seen in young adults and in elderly patients. The disease is composed of 2 distinct entities: the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. Classical HL includes the subgroups nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte rich. Selection of the appropriate therapy is based on accurately assessing the stage of disease. Patients with early-stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, whereas those with advanced-stage disease receive a longer course of chemotherapy without radiation therapy. Currently, more than 80% of all patients with newly diagnosed HL are expected to be long-term survivors. Although many patients respond well to initial therapies and have durable long-term remissions, a subset of patients has resistant disease and experiences relapse even after subsequent high-dose chemotherapy and autologous stem cell transplantation. New therapies are clearly needed for these patients.

Original languageEnglish (US)
Pages (from-to)419-426
Number of pages8
JournalMayo Clinic Proceedings
Volume81
Issue number3
DOIs
StatePublished - Mar 2006

Fingerprint

Hodgkin Disease
Radiotherapy
Lymphocyte Depletion
Drug Therapy
Incidence
Stem Cell Transplantation
Sclerosis
Combination Drug Therapy
Survivors
Young Adult
Therapeutics
Lymphocytes
Recurrence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Management of Hodgkin lymphoma. / Ansell, Stephen M.; Armitage, James Olen.

In: Mayo Clinic Proceedings, Vol. 81, No. 3, 03.2006, p. 419-426.

Research output: Contribution to journalArticle

Ansell, Stephen M. ; Armitage, James Olen. / Management of Hodgkin lymphoma. In: Mayo Clinic Proceedings. 2006 ; Vol. 81, No. 3. pp. 419-426.
@article{a82be37c4d384b32b687ab32c8b3bb0a,
title = "Management of Hodgkin lymphoma",
abstract = "Approximately 7350 new cases of Hodgkin lymphoma (HL) are diagnosed annually in the United States. The incidence of HL has a bimodal pattern, with the highest incidence seen in young adults and in elderly patients. The disease is composed of 2 distinct entities: the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. Classical HL includes the subgroups nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte rich. Selection of the appropriate therapy is based on accurately assessing the stage of disease. Patients with early-stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, whereas those with advanced-stage disease receive a longer course of chemotherapy without radiation therapy. Currently, more than 80{\%} of all patients with newly diagnosed HL are expected to be long-term survivors. Although many patients respond well to initial therapies and have durable long-term remissions, a subset of patients has resistant disease and experiences relapse even after subsequent high-dose chemotherapy and autologous stem cell transplantation. New therapies are clearly needed for these patients.",
author = "Ansell, {Stephen M.} and Armitage, {James Olen}",
year = "2006",
month = "3",
doi = "10.4065/81.3.419",
language = "English (US)",
volume = "81",
pages = "419--426",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "3",

}

TY - JOUR

T1 - Management of Hodgkin lymphoma

AU - Ansell, Stephen M.

AU - Armitage, James Olen

PY - 2006/3

Y1 - 2006/3

N2 - Approximately 7350 new cases of Hodgkin lymphoma (HL) are diagnosed annually in the United States. The incidence of HL has a bimodal pattern, with the highest incidence seen in young adults and in elderly patients. The disease is composed of 2 distinct entities: the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. Classical HL includes the subgroups nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte rich. Selection of the appropriate therapy is based on accurately assessing the stage of disease. Patients with early-stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, whereas those with advanced-stage disease receive a longer course of chemotherapy without radiation therapy. Currently, more than 80% of all patients with newly diagnosed HL are expected to be long-term survivors. Although many patients respond well to initial therapies and have durable long-term remissions, a subset of patients has resistant disease and experiences relapse even after subsequent high-dose chemotherapy and autologous stem cell transplantation. New therapies are clearly needed for these patients.

AB - Approximately 7350 new cases of Hodgkin lymphoma (HL) are diagnosed annually in the United States. The incidence of HL has a bimodal pattern, with the highest incidence seen in young adults and in elderly patients. The disease is composed of 2 distinct entities: the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. Classical HL includes the subgroups nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte rich. Selection of the appropriate therapy is based on accurately assessing the stage of disease. Patients with early-stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, whereas those with advanced-stage disease receive a longer course of chemotherapy without radiation therapy. Currently, more than 80% of all patients with newly diagnosed HL are expected to be long-term survivors. Although many patients respond well to initial therapies and have durable long-term remissions, a subset of patients has resistant disease and experiences relapse even after subsequent high-dose chemotherapy and autologous stem cell transplantation. New therapies are clearly needed for these patients.

UR - http://www.scopus.com/inward/record.url?scp=33644670642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644670642&partnerID=8YFLogxK

U2 - 10.4065/81.3.419

DO - 10.4065/81.3.419

M3 - Article

C2 - 16529147

AN - SCOPUS:33644670642

VL - 81

SP - 419

EP - 426

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 3

ER -